The U.S. Food and Drug Administration (FDA) announced several measures aimed at accelerating the development of psychedelic treatments for severe mental illnesses, following an executive order from President Donald Trump.
FDA's Accelerated Approach to Psychedelic Therapies
The FDA's actions signal a notable shift toward supporting psychedelic-based medicines. These treatments are being targeted for conditions such as:
- Treatment-resistant depression
- Post-traumatic stress disorder (PTSD)
- Various substance use disorders
Robert F. Kennedy Jr., Secretary of the U.S. Department of Health and Human Services, stated that the goal is to accelerate the research, approval, and responsible access to promising mental health treatments under the current administration.
Key Initiatives and Approvals
As part of the announcement, the FDA detailed several specific actions to advance research:
- National Priority Vouchers: The FDA will issue these vouchers to companies researching psilocybin for depression and methylone for PTSD.
- Clinical Trial Authorization: The agency cleared an early-stage clinical trial for noribogaine hydrochloride, a derivative of ibogaine, to potentially treat alcohol use disorder. This marks the first time such a compound has been authorized for study in the U.S.
FDA Commissioner Marty Makary emphasized the potential of these medications to address the national mental health crisis, while stressing the necessity of grounding development in rigorous clinical evidence.
Important Caveats for Researchers and Public
Officials clarified that the authorization for these studies does not equate to drug approval or proof of safety and efficacy. The FDA stated that all data collected during the advancing research phases will be closely monitored.
